We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies
News

AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies

AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies
News

AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaptysBio, Inc., announced that it has signed an agreement with Roche for the development of novel antibody therapeutics.

“We look forward to assisting Roche in building its pipeline of product possibilities as we also apply the platform to generate our own novel product candidates.”

Under the terms of the agreement, AnaptysBio will be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) platform. Roche will receive a worldwide license to develop and commercialize antibodies optimized by AnaptysBio. In addition to a signing fee paid by Roche, AnaptysBio will be eligible to receive milestone payments and royalties upon product sales.

“AnaptysBio’s proprietary SHM platform provides a powerful new approach for evolving existing antibodies to meet challenging therapeutic design goals such as those specified by Roche,” said Tom Smart, chairman and chief executive officer for AnaptysBio. “We look forward to assisting Roche in building its pipeline of product possibilities as we also apply the platform to generate our own novel product candidates.”
Advertisement